Benitec Biopharma Inc. (BNTC) reported positive interim clinical data from the 90-day timepoint following the administration of BB-301 to the study's first subject treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study in Oculopharyngeal Muscular Dystrophy.
Benitec Biopharma (BNTC) Announces $40M Placement at $4 80/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Wall Street Breakfast Podcast: TikTok Bill Fast Track
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Benitec Biopharma (BNTC) Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Two Rare Disease Drug Developers Raise Combined $152 5 Million in PIPE Offerings
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.